Search reports, ask a question, or jump to a page.
The problem
Intervention: Provision of RSV monoclonal antibodies (nirsevimab and/or palivizumab) to at-risk infants through targeted hospital-level programs
Who it was tested with: High-risk neonates and infants (primarily premature infants <37 weeks gestation) at five Victorian hospitals.
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"This study was descriptive and exploratory, and no formal effectiveness or comparative analyses were undertaken." The study describes implementation and tracks breakthrough infections but cannot establish whether the intervention prevented severe disease, improved health outcomes, or compare effectiveness against standard care, making the evidence tier practitioner-level and the outcome direction inconclusive.
No formal effectiveness or comparative analyses were undertaken; no control or comparison group; descriptive and exploratory design only; limited to one Australian state; no assessment of clinical severity of breakthrough infections or longer-term outcomes.
Across countries and designs
6 studies · 17 countries
